TBX2 maps to chromosome 17q23.2, a region that is aberrantly amplified in over 40% of breast cancers [1], 40% of melanomas [2], 40% of ovarian [3], 56% of endometrial [4], and 60% of pancreatic cancers [5], correlating with poor clinical outcome. This evidence concerns the gene TBX2 and melanoma.